The recent increase in public awareness of Intellectual Property (IP) has not necessarily led to a greater understanding of its generation, use or relevance to modern business. Although the term “risk-management” is generally understood, very few companies understand the risks associated with IP, let alone have a strategy for dealing with these risks.

For many companies in the life sciences sector, IP is a key asset used to support their efforts to secure private equity funding. As a consequence, investors are placing greater emphasis on IP due diligence during the investment process. IP issues may undermine the ability to . . .

This content is restricted to subscribers. To view this content please register an account.

Register now

If you are already a subscriber, please login below.